This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...